ClearBridge Energy MLP Total Return Fund Inc. Form DEF 14A March 08, 2017

### **SCHEDULE 14A**

(Rule 14a-101)

## INFORMATION REQUIRED IN PROXY STATEMENT

### **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the

**Securities Exchange Act of 1934** 

(Amendment No. )

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

**Preliminary Proxy Statement** 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2))

**Definitive Proxy Statement** 

**Definitive Additional Materials** 

Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12

CLEARBRIDGE ENERGY MLP TOTAL RETURN FUND INC.

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by the registration statement number, on the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:

CLEARBRIDGE ENERGY MLP TOTAL RETURN FUND INC.

(NYSE: CTR)

### 620 Eighth Avenue, 49th Floor, New York, New York 10018

### NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

March 8, 2017

To the Stockholders:

The Annual Meeting of Stockholders of ClearBridge Energy MLP Total Return Fund Inc. (the Fund) will be held at 620 Eighth Avenue, 49th Floor (at 41st Street), New York, New York, on Friday, April 7, 2017 at 11:30 a.m., New York time, for the following purposes:

- 1. A proposal to elect three Class II Directors to the Fund s Board of Directors; and
- 2. The transaction of such other business as may properly come before the meeting or any adjournments or postponements thereof.

The Board of Directors has fixed the close of business on January 23, 2017 as the record date for the determination of stockholders entitled to notice of, and to vote at, the meeting and any adjournments or postponements thereof.

By Order of the Board of Directors

Robert I. Frenkel

Secretary

March 8, 2017

IT IS IMPORTANT THAT YOUR SHARES BE REPRESENTED AT THE MEETING IN PERSON OR BY PROXY; IF YOU DO NOT EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN THE PROXY CARD (which will be made available to you separately) OR PROVIDE VOTING INSTRUCTIONS BY TELEPHONE OR VIA THE INTERNET.

### **Instructions for Signing Proxy Cards**

The following general rules for signing proxy cards may be of assistance to you and avoid the time and expense to the Fund in validating your vote if you fail to sign your proxy card properly.

- 1. Individual Accounts: Sign your name exactly as it appears in the registration on the proxy card.
- 2. *Joint Accounts:* Either party may sign, but the name of the party signing should conform exactly to a name shown in the registration.
- 3. *All Other Accounts:* The capacity of the individual signing the proxy card should be indicated unless it is reflected in the form of registration. For example:

Registration	Valid Signature
Corporate Accounts	
(1) ABC Corp	ABC Corp. (by John Doe, Treasurer)
(2) ABC Corp	John Doe, Treasurer
(3) ABC Corp., c/o John Doe, Treasurer	John Doe
(4) ABC Corp. Profit Sharing Plan	John Doe, Trustee
Trust Accounts	
(1) ABC Trust	Jane B. Doe, Trustee
(2) Jane B. Doe, Trustee, u/t/d 12/28/78	Jane B. Doe
<b>Custodial or Estate Accounts</b>	
(1) John B. Smith, Cust., f/b/o John B. Smith, Jr. UGMA	John B. Smith
(2) John B. Smith	John B. Smith, Jr., Executor
T	F

### **Instructions for Telephone/Internet Voting**

Various brokerage firms may offer the convenience of providing you with voting instructions via telephone or the Internet for shares held through such firms. Instructions for Internet and telephonic voting are included with the proxy card or voting instruction form.

CLEARBRIDGE ENERGY MLP TOTAL RETURN FUND INC.

(NYSE: CTR)

### 620 Eighth Avenue, 49th Floor, New York, New York 10018

### PROXY STATEMENT

This proxy statement is furnished in connection with the solicitation by the Board of Directors (the Board ) of ClearBridge Energy MLP Total Return Fund Inc. (the Fund ) of proxies to be voted at the Annual Meeting of Stockholders of the Fund to be held at 620 Eighth Avenue (at 41st Street), 49th Floor, New York, New York, on Friday, April 7, 2017 at 11:30 a.m., New York time, and at any adjournments or postponements thereof (the Meeting ), for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders (the Notice ).

This Proxy Statement and the accompanying materials are being made available to stockholders on or about March 8, 2017.

The Fund is organized as a Maryland corporation and is a registered investment company.

Legg Mason Partners Fund Advisor, LLC ( LMPFA ), whose principal business address is 620 Eighth Avenue, New York, NY 10018, is the Fund s investment adviser and administrator. Pursuant to a sub-advisory agreement with ClearBridge Investments, LLC (formerly ClearBridge Advisors, LLC) ( ClearBridge ), located at 620 Eighth Avenue, New York, New York 10018, ClearBridge serves as the Fund s subadviser. LMPFA and ClearBridge are both wholly-owned subsidiaries of Legg Mason, Inc. ( Legg Mason ).

Even if you plan to attend the Meeting, please sign, date and return a proxy card, or provide voting instructions by telephone or over the Internet. If you vote by telephone or over the Internet, you will be asked to enter a unique code that has been assigned to you and which is printed on your proxy card. This code is designed to confirm your identity, provide access into the voting sites and confirm that your instructions are properly recorded. If you require additional information, please call toll free at 1-866-875-8614.

All properly executed proxies received prior to the Meeting will be voted at the Meeting in accordance with the instructions marked thereon or otherwise as provided therein. Unless instructions to the contrary are marked, shares represented by the proxies will be voted FOR the election of each nominee in Proposal 1. Stockholders who execute proxies may revoke them at any time before they are voted by filing with the Fund a written notice of revocation, by delivering a duly executed proxy bearing a later date or by attending the Meeting and voting in person. In accordance with the Fund s By-Laws, a quorum is constituted by the presence in person or by proxy of the holders of record of a majority of the outstanding shares of the Fund s common stock entitled to vote at the Meeting. For purposes of determining the presence of a quorum for transacting business at the Meeting, abstentions will be treated as shares that are present but which have not been voted.

The Board has fixed the close of business on January 23, 2017 as the record date (the Record Date ) for the determination of stockholders of the Fund entitled to notice of and to vote at the Meeting or any adjournment or postponement thereof. The Fund has two classes of shares: Common Stock, par value \$.001 per share, and fixed rate Mandatory Redeemable Preferred Stock (Preferred Shares), which have a liquidation

preference of \$100,000 per share (collectively with the Common Stock, the Shares ). Stockholders of the Fund on that date will be entitled to one vote on each matter for each share held, and a fractional vote with respect to fractional shares, with no cumulative voting rights. At the Record Date, the Fund had outstanding 38,400,142 shares of Common Stock, par value \$0.001 per share, and 140 Preferred Shares.

Annual reports are sent to stockholders of record of the Fund following the Fund s fiscal year end. The Fund will furnish, without charge, a copy of its annual report and most recent semi-annual report succeeding the annual report, if any, to a stockholder upon request. Such requests should be directed to the Fund at 620 Eighth Avenue, 49th Floor, New York, New York 10018 or by calling toll free at 888-777-0102. Copies of annual and semi-annual reports of the Fund are also available on the Fund s website at Imcef.com or on the EDGAR Database on the Securities and Exchange Commission s Internet site at www.sec.gov.

Please note that only one annual or semi-annual report or Proxy Statement may be delivered to two or more stockholders of the Fund who share an address, unless the Fund has received instructions to the contrary. To request a separate copy of an annual or semi-annual report or the Proxy Statement, or for instructions as to how to request a separate copy of these documents or as to how to request a single copy if multiple copies of these documents are received, stockholders should contact the Fund at the address and phone number set forth above.

### **Vote Required and Manner of Voting Proxies**

A quorum of stockholders is required to take action at the Meeting. A majority of the shares of the Fund entitled to vote at the Meeting, represented in person or by proxy, will constitute a quorum of stockholders at the Meeting.

Votes cast by proxy or in person at the Meeting will be tabulated by the inspector of election appointed for the Meeting. The inspector of election, who is an employee of the proxy solicitor engaged by the Fund, will determine whether or not a quorum is present at the Meeting. The inspector of election will treat abstentions and broker non-votes (i.e., shares held by brokers or nominees, typically in street name, as to which proxies have been returned but (a) instructions have not been received from the beneficial owners or persons entitled to vote and (b) the broker or nominee does not have discretionary voting power on a particular matter) as present for purposes of determining a quorum.

If you hold shares directly (not through a broker-dealer, bank or other financial intermediary) and if you return a signed proxy card that does not specify how you wish to vote on a proposal, your shares will be voted FOR Proposal 1.

Broker-dealer firms holding shares of the Fund in street name for the benefit of their customers and clients will request the instructions of such customers and clients on how to vote their shares on each Proposal before the Meeting. A signed proxy card or other authorization by a beneficial owner of Fund shares that does not specify how the beneficial owner s shares should be voted on a proposal will be deemed an instruction to vote such shares in favor of Proposal 1.

If you hold shares of the Fund through a service agent that has entered into a service agreement with the Fund, the service agent may be the record holder of your shares. At the Meeting, a service agent will vote shares for which it receives instructions from its customers in accordance with those instructions. A signed proxy card or other authorization by a stockholder that does not specify how the stockholder s shares should be voted on a proposal may be deemed to authorize a service agent to vote such shares in favor of Proposal 1.

Depending on its policies, applicable law or contractual or other restrictions, a service agent may be permitted to vote shares with respect to which it has not received specific voting instructions from its customers. In those cases, the service agent may, but may not be required to, vote such shares in the same proportion as those shares for which the service agent has received voting instructions. This practice is commonly referred to as echo voting.

If you beneficially own shares that are held in street name through a broker-dealer or that are held of record by a service agent and if you do not give specific voting instructions for your shares, they may not be voted at all or, as described above, they may be voted in a manner that you may not intend. Therefore, you are strongly encouraged to give your broker-dealer or service agent specific instructions as to how you want your shares to be voted.

### **Required Vote**

Two Directors are elected by a plurality of the votes cast by the holders of shares of the Fund s Common Stock and Preferred Shares voting together as a single class present in person or represented by proxy at a Meeting at which a quorum is present.

One Director is elected by plurality of the votes cast only by the holders of shares of the Fund s Preferred Shares present in person or represented by proxy at a Meeting at which a quorum is present.

For purposes of the election of Directors, abstentions and broker non-votes will not be considered votes cast, and do not affect the plurality vote required for the election of Directors.

If the necessary quorum to transact business or the vote required to approve Proposal 1 is not obtained at the Meeting, the chairman of the Meeting or the persons named as proxies may propose one or more adjournments or postponements of the Meeting in accordance with applicable law to permit further solicitation of proxies. If in the judgment of the chairman of the Meeting, it is advisable to defer action on the Proposal, the chairman of the Meeting may propose one or more adjournments of the Meeting with respect to the Proposal for a reasonable period or periods. The Meeting may be adjourned up to 120 days after the original record date for the Meeting without further notice other than announcement at the Meeting.

Important Notice Regarding the Availability of Proxy Materials for the Meeting to be Held on April 7, 2017

The proxy statement and related materials are available at www.proxy-direct.com/lem28526.

### **Proposal No. 1: Election of Directors**

In accordance with the Fund s Charter, the Board shall be divided into three classes at this annual meeting of stockholders: Class I, Class II and Class III. The Directors serving in Class II have terms expiring at the Meeting, and they have been nominated by the Board of Directors for election at the Meeting to serve for a term of three years (until the 2020 Annual Meeting of Stockholders), or until their successors have been duly elected and qualified or until they resign or are otherwise removed. The terms of office of the remaining Class I and Class III Directors expire at the year 2019 and 2018 Annual Meeting of Stockholders, respectively, or thereafter until their successors have been duly elected and qualified or until they resign or are otherwise removed. The effect of these staggered terms is to limit the ability of other entities or persons to acquire control of the Fund by delaying the replacement of a majority of the Board of Directors.

Under the terms of the Fund s charter, the preferred stockholders are entitled as a class, to the exclusion of the common stockholders, to elect two Directors of the Fund (the Preferred Share Directors ). Leslie H. Gelb and Eileen A. Kamerick have been designated as the Preferred Share Directors. Mr. Gelb, as a Class II Director

is nominated for election at this meeting. The charter further provides that the remaining nominees shall be elected by holders of Common Stock and Preferred Shares, voting together as a single class.

The persons named in the proxy intend to vote at the Meeting (unless directed not to vote) FOR the election of the nominees named below. Each of the nominees is currently a member of the Fund s Board of Directors and has indicated that he or she will serve if elected. However, if any nominee should be unable to serve, the proxy will be voted for any other person determined by the persons named in the proxy in their discretion.

Certain information concerning the nominees for Directors of the Fund and other Directors of the Fund is set forth in the following table.

### **Persons Nominated for Election as Directors**

Name, Address and Birth Year	Position(s) Held with Fund	Term of Office and Length Time Served	Por	Other Directorships Held by Director
			al Meeting of Stockholders	
NON-INTERESTED DIRI Leslie H. Gelb c/o Chairman of the Fund Legg Mason & Co. LLC ( Legg Mason & Co. )  620 Eighth Avenue, 49th Floor New York, NY 10018 Birth year: 1937	Director and Member of Audit, Nominating, Compensation, Pricing and Valuation Committees	Since 2012	President Emeritus (since 2003), formerly Senior Board Fellow (2003-2015) and President (prior to 2003) of The Council on Foreign Relations; formerly, Columnist, Deputy Editorial Page Editor and Editor, Op-Ed Page, <i>The New York Times</i>	Director of two registered investment companies advised by Aberdeen Asset Management Asia Limited (since 1994); Director, Encyclopedia Britannica; Director, Centre Partners IV and V, LP and Affiliates
William R. Hutchinson c/o Chairman of the Fund Legg Mason & Co. 620 Eighth Avenue, 49th Floor New York, NY 10018 Birth year: 1942	Director and Member of Audit, Nominating, Compensation, Pricing and Valuation Committees	Since 2012	President, W.R. Hutchinson & Associates Inc. (consulting)	Director (Non-Executive Chairman of the Board (since December 1, 2009)), Associated Banc-Corp. (since 1994)

- \*\* The term Fund Complex means two or more registered investment companies that:
  - (a) Hold themselves out to investors as related companies for purposes of investment and investor services; or
  - (b) Have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other registered investment companies.

4

	Term of Office and		Number of Portfolios in Fund	
` '			-	Other
			•	Directorships
		U		<b>Held by Director</b>
	ng until 2020	Annual Meeting of Sto	ckholders	
•			149	None
	2015			
and Chief				
Executive				
Officer		of 156 funds associated		
		with LMPFA or its		
		affiliates (since 2015);		
		President and Chief		
		<b>Executive Officer of</b>		
		LMPFA (since 2015);		
		formerly, Senior Vice		
		President of LMPFA		
		(2015). Formerly,		
		•	,	
		Mason Capital		
		•		
		, , ,		
		2 2	-	
		Counsel & Trust Co.		
		(2000 to 2007).		
	Chairman, President and Chief Executive	Position(s) Length Held with Time Fund Served irector serving until 2020 OMINEE Chairman, Since President 2015 and Chief Executive	Position(s) Length Held with Time Principal Occupations Fund Served During Past Five Year irector serving until 2020 Annual Meeting of Sto OMINEE Chairman, Since Managing Director of President 2015 Legg Mason & Co. and Chief (since 2016); Officer Executive and/or Trustee/Director Officer of 156 funds associated with LMPFA or its affiliates (since 2015); President and Chief Executive Officer of LMPFA (since 2015); formerly, Senior Vice President of LMPFA (2015). Formerly, Director of ClearBridge LLC (formerly, Legg Mason Capital Management, LLC) (2007 to 2014); Managing Director of Legg Mason Investment Counsel & Trust Co.	Term of Office and Position(s) Held with Time Principal Occupations Overseen by Fund Served During Past Five Years Director irector serving until 2020 Annual Meeting of Stockholders OMINEE Chairman, Since Managing Director of 149 President 2015 Legg Mason & Co. and Chief (since 2016); Officer Executive and/or Trustee/Director Officer of 156 funds associated with LMPFA or its affiliates (since 2015); President and Chief Executive Officer of LMPFA (since 2015); Fresident and Chief Executive Officer of LMPFA (2015). Formerly, Senior Vice President of LMPFA (2015). Formerly, Director of ClearBridge, LLC (formerly, Legg Mason Capital Management, LLC) (2007 to 2014); Managing Director of Legg Mason Investment Counsel & Trust Co.

<sup>\*</sup> Ms. Trust is an interested person as defined in the Investment Company Act of 1940, as amended (the 1940 Act ), because she is an officer of LMPFA and certain of its affiliates.

<sup>\*\*</sup> The term Fund Complex means two or more registered investment companies that:

<sup>(</sup>a) Hold themselves out to investors as related companies for purposes of investment and investor services; or

<sup>(</sup>b) Have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other registered investment companies.

Name, Address and Birth Year The following table provide Class III Directors serving	until the 2018 Ann			Director	Other Directorships Held by Director
NON-INTERESTED DIRE Eileen A. Kamerick c/o Chairman of the Fund Legg Mason & Co. 620 Eighth Avenue, 49th Floor New York, NY 10018 Birth year: 1958	Director and Member of Audit, Nominating, Compensation, Pricing and Valuation Committees	Since 2013	National Association of Corporate Directors Board Leadership Fellow and financial expert; Adjunct Professor, Washington University in St. Louis and University of Iowa law schools (since 2007); formerly, Senior Advisor to the Chief Executive Officer and Executive Vice President and Chief Financial Officer of ConnectWise, Inc. (software and services company) (2015 to 2016); Chief Financial Officer, Press Ganey Associates (health care informatics company) (2012 to 2014); Managing Director and Chief Financial Officer, Houlihan Lokey (international investment bank) and President, Houlihan Lokey Foundation (2010 to 2012)		Hochschild Mining plc (precious metals company) (since 2016); Director of Associated Banc-Corp (financial services company) (since 2007); Westell Technologies, Inc. (technology company) (2003 to 2016)
Dr. Riordan Roett c/o Chairman of the Fund Legg Mason & Co.	Director and Member of Audit,	Since 2012	The Sarita and Don Johnston Professor of Political Science	27	None

620 Eighth Avenue, 49th Nominating, and Director of Floor Compensation, Latin American New York, NY 10018 Pricing and Studies, Paul H. Birth year: 1938 Valuation Nitze School of Committees Advanced International

Studies, The Johns Hopkins University

(since 1973)

- (a) Hold themselves out to investors as related companies for purposes of investment and investor services; or
- (b) Have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other registered investment companies.

<sup>\*\*</sup> The term Fund Complex means two or more registered investment companies that:

Robert D. Agdern   Director and   Since   Member of the Advisory   27   None	Name, Address and Birth Year	Position(s) Held with Fund	Term of Office and Length Time Served	P Co Principal Occupation Ov During Past Five Years I		* byOther Directorships
Member of 2015 Committee of the C/o Chairman of the Fund Audit, Nominating, Research Center at the Religing Mason & Co. Compensation, Pricing and School of Business, Valuation Northwestern University (2002-2016); Deputy General Counsel responsible for western hemisphere matters for hemisphere matters for BP PLC from 1999 to 2001; Associate General Coursel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class 1 Directors serving until 2019 Annual Meeting of Stockholders NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None Cof Chairman of the Fund Legg Mason & Co. Audit, Nominating, Pricing and Since New York, NY 10018 Pricing and Committees Pricing and Counsel at Amoco Counsel at Amoco Committees President, Colman 27 None Compensation, Pricing and Committees President, Colman 27 None Compensation, Pricing and Committees President, Colman 27 None Compensation, Pricing and Committees President, Colman 27 None Committees Pricing and Compensation, Pricing and Pric	_		_		27	None
Legg Mason & Co. Compensation, Pricing and Pricing Bricing	11000112711800111			•		1,0110
Legg Mason & Co. Pricing and School of Business, 620 Eighth Avenue, 49th Valuation Floor New York, NY 10018  Nominating, Compensation, New York, NY 10018  Nominating of Compensation, New York, NY 10018  Nominating, Compensation, Nominating, Counsel, Pfizer, Inc. Nominating, Counsel, Pfizer, Inc. Nominating, Counsel, Pfizer, Inc. Nominating, Counsel, Pfizer, Inc. Nominating, Compensation, New York, NY 10018	c/o Chairman of the Fund	· ·		Dispute Resolution		
620 Eighth Avenue, 49th Floor Committees Counsel of western hemisphere matters for PP LC from 1999 to 2001; Associate General Counsel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders NON-INTERESTED DIRECTORS Carol L. Colman Corporation Committees Carol L. Colman Corporation Member of 2012 Consulting Co. Audit, Nominating, Floor Compensation, New York, NY 10018 Pricing and Valuation Committees Compensation, New York, NY 10018 Director and Collairman of the Fund Legg Mason & Co. Audit, Nominating, Floor Committees Committees Counsel, Pfizer, Inc. Nominating, Floor Compensation, Nominating, Floor Compensation, Nominating, Floor Committees Counsel, Pfizer, Inc. Nominating, Floor Compensation, Floor Compensation, Nominating, Floor Compensation, Nominating, Floor Compensation, Floor Compensation Counsel, Pfizer, Inc. Floor Counsel, Pfizer, Inc. Floor Counsel Amoco Counsel Amoco Counsel Amoco Counsel Amoco Counsel Amoco Congression Counsel Amoco Counse	Legg Mason & Co.	Compensation,		Kellogg Graduate		
Floor Committees (2002-2016); Deputy General Counsel responsible for western hemisphere matters for Pear of birth: 1950	620 Eighth Avenue, 49th	-				
Year of birth: 1950  Year of birth: 1950  Pel PLC from 1999 to 2001; Associate General Counsel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, Compensation, New York, NY 10018  Pricing and Since Retired; formerly, 27 None Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None Colonality Since Compensation, New York, NY 10018  Pricing and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Oirector and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Oirector and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Oirector and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Oirector and Since Retired; formerly, 27 None Colonality Since Committees  Daniel P. Cronin Compensation, New York, NY 10018  Pricing and Since Retired; formerly, 27 None Colonality Since Compensation, New York, NY 10018  Pricing and Since Retired; formerly, 27 None Colonality Since Compensation, New York, NY 10018  Pricing and Since Retired; formerly, 27 None Colonality Since Compensation, New York, NY 10018	_	Committees		(2002-2016); Deputy		
Year of birth: 1950  Pear of birth: 1950  RP PLC from 1999 to 2001; Associate General Counsel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, Compensation, New York, NY 10018 Pricing and Pricing and Pricing and Birth year: 1946  Daniel P. Cronin Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None  Compensation, New York, NY 10018 Pricing and Pricing Associate General Counsel, Pfizer, Inc.  Compensation, New York, NY 10018 Pricing and Pricing an	New York, NY 10018			1		
Counsel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None c/o Chairman of the Fund Member of 2012 Consulting Co. Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel at Amoco Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  27 None 28 None 29 None 20 Consulting Co. 29 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and	Year of birth: 1950			_		
Corporation responsible for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General  Legg Mason & Co. Audit, Counsel, Pfizer, Inc.  OCOMPENSATION NONINATIONS  Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General  Legg Mason & Co. Audit, Counsel, Pfizer, Inc.						
for corporate, chemical, and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit,  620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None  c/o Chairman of the Fund Member of 2012 Associate General  Legg Mason & Co. Audit,  Committees  Counsel, Pfizer, Inc.  Counsel, Pfizer, Inc.  Counsel, Pfizer, Inc.						
and refining and marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and				-		
marketing matters and special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Pricing and Pricing Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and				_		
Special assignments from 1993 to 1998 (Amoco merged with British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None  c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc.  620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and				_		
Class I Directors serving until 2019 Annual Meeting of Stockholders   NON-INTERESTED DIRECTORS						
British Petroleum in 1998 forming BP PLC).  Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None  c/o Chairman of the Fund Member of 2012 Associate General  Legg Mason & Co. Audit, Counsel, Pfizer, Inc.  620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and				_		
Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None  c/o Chairman of the Fund Member of 2012 Associate General  Legg Mason & Co. Audit, Counsel, Pfizer, Inc.  620 Eighth Avenue, 49th Nominating, Floor Compensation,  New York, NY 10018 Pricing and				(Amoco merged with		
Class I Directors serving until 2019 Annual Meeting of Stockholders  NON-INTERESTED DIRECTORS  Carol L. Colman Director and Since President, Colman 27 None  c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc.  620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and						
Carol L. Colman Director and Since President, Colman 27 None c/o Chairman of the Fund Member of 2012 Consulting Co.  Legg Mason & Co. Audit, 620 Eighth Avenue, 49th Nominating, Ploor Compensation, Committees  Daniel P. Cronin Director and Since Retired; formerly, c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, Pricing and Pricing and Since Retired; formerly, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and				1998 forming BP PLC).		
Carol L. Colman c/o Chairman of the Fund Legg Mason & Co. Legg Mason & Co. 620 Eighth Avenue, 49th Floor Nominating, New York, NY 10018 Pricing and Birth year: 1946 Daniel P. Cronin c/o Chairman of the Fund Member of 2012 Consulting Co.			Meeting of	Stockholders		
Legg Mason & Co.  Audit,  620 Eighth Avenue, 49th  Floor  Compensation,  New York, NY 10018  Birth year: 1946  Valuation  Committees  Daniel P. Cronin  C/o Chairman of the Fund  Member of  Legg Mason & Co.  Audit,  Counsel, Pfizer, Inc.  Since  Compensation,  New York, NY 10018  Pricing and  Since  Retired; formerly,  Associate General  Counsel, Pfizer, Inc.  Counsel, Pfizer, Inc.	Carol L. Colman	Director and	Since	President, Colman	27	None
620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and		Member of	2012	Consulting Co.		
Floor Compensation, New York, NY 10018 Pricing and Birth year: 1946 Valuation Committees  Daniel P. Cronin Director and Since Retired; formerly, 27 None c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and		•				
New York, NY 10018  Birth year: 1946  Valuation Committees  Daniel P. Cronin  C/o Chairman of the Fund  Legg Mason & Co.  620 Eighth Avenue, 49th Nominating, Floor  New York, NY 10018  Pricing and  Since Retired; formerly, 27 None Counsel, Pfizer, Inc.  Counsel, Pfizer, Inc.	_	_				
Birth year: 1946  Valuation Committees  Daniel P. Cronin  Clo Chairman of the Fund  Director and Since  Clo Chairman of the Fund  Member of 2012  Associate General  Legg Mason & Co.  Audit,  Counsel, Pfizer, Inc.  Compensation,  New York, NY 10018  Pricing and		_				
Committees  Daniel P. Cronin C/o Chairman of the Fund Director and Member of		-				
c/o Chairman of the Fund Member of 2012 Associate General Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and	Dittil year. 1940					
Legg Mason & Co. Audit, Counsel, Pfizer, Inc. 620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and	Daniel P. Cronin	Director and	Since	Retired; formerly,	27	None
620 Eighth Avenue, 49th Nominating, Floor Compensation, New York, NY 10018 Pricing and			2012			
Floor Compensation, New York, NY 10018 Pricing and				Counsel, Pfizer, Inc.		
New York, NY 10018 Pricing and	_	_				
		_				
Birth year: 1940 Valuation	Birth year: 1946	Valuation				

- \*\* The term Fund Complex means two or more registered investment companies that:
  - (a) Hold themselves out to investors as related companies for purposes of investment and investor services; or
  - (b) Have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other registered investment companies.

7

Name, Address and Birth Year Class I Director serving un NON-INTERESTED DIRECTOR	Position(s) Held with Fund itil 2019 Annual I	Term of Office and Length Time Served Meeting of S	Comp Principal Occupation Overse During Past Five Years Direct	f olios n nd lex* een b	* yOther Directorships
Paolo M. Cucchi c/o Chairman of the Fund Legg Mason & Co. 620 Eighth Avenue, 49th Floor New York, NY 10018 Birth year: 1941	Director and Member of Audit, Nominating, Compensation, Pricing and Valuation Committees	Since 2012	Emeritus Professor of French and Italian at Drew University (since 2014); formerly, Professor of French and Italian at Drew University (2009 to 2014); Vice President and Dean of College of Liberal Arts at Drew University (1984 to 2009)	27	None

<sup>\*\*</sup> The term Fund Complex means two or more registered investment companies that:

<sup>(</sup>a) Hold themselves out to investors as related companies for purposes of investment and investor services; or

<sup>(</sup>b) Have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other registered investment companies.

Each of the Directors has served as a director of the Fund as indicated in the table above. The Directors were selected to join the Board based upon the following as to each Board Member: his or her character and integrity; such person s service as a board member of other funds in the Legg Mason fund complex; such person s willingness to serve and willingness and ability to commit the time necessary to perform the duties of a Director; as to each Director other than Ms. Trust, his or her status as not being an interested person as defined in the 1940 Act; and, as to Ms. Trust, her role with Legg Mason. No factor, by itself, was controlling.

In addition to the information provided in the table included above, each Director possesses the following attributes: Mr. Agdern, experience in business and as a legal professional; Ms. Colman, experience as a consultant and investment professional; Mr. Cronin, legal and managerial experience; Mr. Cucchi, experience as a college professor and leadership experience as an academic dean; Mr. Gelb, academic and world affairs and foreign relations experience and service as a board member of other registered investment companies; Mr. Hutchinson, experience in accounting and working with auditors, consulting, business and finance and service as a board member of another highly regulated financial services company; Ms. Kamerick, experience in business and finance, including financial reporting, and experience as a board member of another highly regulated financial services company; Dr. Roett, expertise in Latin and South American societies and economies and academic leadership experience; and Ms. Trust, investment management and risk oversight experience as an executive and portfolio manager and leadership roles within Legg Mason and affiliated entities. References to the qualifications, attributes and skills of the Directors are pursuant to requirements of the Securities and Exchange Commission, do not constitute holding out of the Board or any Director as having any special expertise or experience, and shall not impose any greater responsibility or liability on any such person or on the Board by reason thereof.

### **Security Ownership of Management**

The following table provides information concerning the dollar range of equity securities owned beneficially by each Director and nominee for election as Director as of December 31, 2016:

		Aggregate Dollar Range <sup>(1)</sup> of Equity Securities
	Dollar Range <sup>(1)</sup> of Equity	in all Funds Overseen by Director/Nominee
Name of Director/Nominee NON-INTERESTED	Securities in the Fund	in Family of Investment Companies <sup>(2)</sup>
DIRECTORS		<b>.</b>
Robert D. Agdern	A	E
Carol L. Colman	A	E
Daniel P. Cronin	C	E
Paolo M. Cucchi	A	C
Leslie H. Gelb	A	A
William R. Hutchinson	A	E
Eileen A. Kamerick	В	E
Dr. Riordan Roett	A	C
INTERESTED DIRECTOR		
Jane E. Trust	A	E

<sup>(1)</sup> The dollar ranges are as follows: A = None; B = \$1-\$10,000; C = \$10,001-\$50,000; D = \$50,001-\$100,000; E Over \$100,000.

(2) The term, Family of Investment Companies , means any two or more registered investment companies that share the same investment adviser or principal underwriter or hold themselves out to investors as related companies for purposes of investment and investor services.

At January 23, 2017, the nominees, Directors and officers of the Fund as a group beneficially owned less than 1% of the outstanding shares of the Fund s Common Stock and Preferred Shares.

No Director or nominee for election as Director who is not an interested person of the Fund as defined in the 1940 Act, nor any immediate family members, to the best of the Fund s knowledge, had any interest in the Fund s investment adviser, or any person or entity (other than the Fund) directly or indirectly controlling, controlled by, or under common control with Legg Mason as of December 31, 2016.

### **Director Compensation**

Under the federal securities laws, and in connection with the Meeting, the Fund is required to provide to stockholders in connection with the Meeting information regarding compensation paid to the Directors by the Fund, as well as by the various other investment companies advised by LMPFA. The following table provides information concerning the compensation paid to each Director by the Fund during the fiscal year ended November 30, 2016 and the total compensation paid to each Director during the calendar year ended December 31, 2016. The Directors listed below are members of the Fund s Audit, Nominating, Compensation and Pricing and Valuation Committees, as well as committees of the boards of certain other investment companies advised by LMPFA. Accordingly, the amounts provided in the table include compensation for service on all such committees. The Fund does not provide any pension or retirement benefits to Directors. In addition, no remuneration was paid during the fiscal year ended November 30, 2016 by the Fund to Ms. Trust who is an interested person as defined in the 1940 Act.

Name of Directors	Aggregate Compensation from the Fund for Fiscal Year Ended 11/30/16(\$)	Total Compensation from the Fund and Fund Complex <sup>(1)</sup> for Calendar Year Ended 12/31/16(\$)
Directorships <sup>(2)</sup>	1 car Ended 11/30/10(φ)	Calcidat Teat Ended 12/31/10(\$)
_	14555	250,222
Robert D. Agdern	14,555	259,232
Carol L. Colman	16,495	290,880
Daniel P. Cronin	16,495	290,880
Paolo M. Cucchi	15,696	276,056
Leslie H. Gelb	15,696	276,056
William R. Hutchinson	18,352	325,471
Eileen A. Kamerick	17,291	305,705
Dr. Riordan Roett	15,696	276,056

- (1) Fund Complex means two or more Funds (a registrant or, where the registrant is a series company, a separate portfolio of the registrant) that hold themselves out to investors as related companies for purposes of investment and investor services or have a common investment adviser or have an investment adviser that is an affiliated person of the investment adviser of any of the other Funds.
- (2) Each Director currently holds 27 investment company directorships within this Fund Complex.

### Responsibilities of the Board of Directors

The Board of Directors is responsible under applicable state law for overseeing generally the management and operations of the Fund. The Directors oversee the Fund s operations by, among other things, meeting at its regularly scheduled meetings and as otherwise needed with the Fund s management and evaluating the performance of the Fund s service providers including LMPFA, ClearBridge, the custodian and the transfer agent. As part of this process, the Directors consult with the Fund s independent auditors and with their own separate independent counsel.

The Directors review the Fund s financial statements, performance, net asset value and market price and the relationship between them, as well as the quality of the services being provided to the Fund. As part of this process, the Directors review the Fund s fees and expenses in light of the nature, quality and scope of the

services being received while also seeking to ensure that the Fund continues to have access to high quality services in the future.

The Board of Directors has four regularly scheduled meetings each year, and additional meetings may be scheduled as needed. In addition, the Board has a standing Audit Committee, Corporate Governance and Nominating Committee (the Nominating Committee), Compensation Committee and Pricing and Valuation Committee that meet periodically and whose responsibilities are described below.

During the fiscal year ended November 30, 2016, the Board of Directors held four regular meetings and eight special meetings. Each Director attended at least 75% of the aggregate number of meetings of the Board and the committees for which he or she was eligible. The Fund does not have a formal policy regarding attendance by Directors at annual meetings of stockholders.

Each of the Audit Committee, the Nominating Committee, Compensation Committee and Pricing and Valuation Committee is composed of all Directors who have been determined not to be interested persons of the Fund, LMPFA, ClearBridge or their affiliates within the meaning of the 1940 Act, and who are independent as defined in the New York Stock Exchange listing standards (Independent Directors), and is chaired by an Independent Director. The Board in its discretion from time to time may establish *ad hoc* committees.

The Board of Directors is currently comprised of nine directors, eight of whom are Independent Directors. Jane E. Trust serves as Chairman of the Board. Ms. Trust is an interested person of the Fund. The appointment of Ms. Trust as Chairman reflects the Board s belief that her experience, familiarity with the Fund s day-to-day operations and access to individuals with responsibility for the Fund s management and operations provides the Board with insight into the Fund s business and activities and, with her access to appropriate administrative support, facilitates the efficient development of meeting agendas that address the Fund s business, legal and other needs and the orderly conduct of board meetings. Mr. Hutchinson serves as Lead Independent Director. The Chairman develops agendas for Board meetings in consultation with the Lead Independent Director and presides at all meetings of the Board. The Lead Independent Director, among other things, chairs executive sessions of the Independent Directors, serves as a spokesperson for the Independent Directors and serves as a liaison between the Independent Directors and the Fund s management between Board meetings. The Independent Directors regularly meet outside the presence of management and are advised by independent legal counsel. The Board also has determined that its leadership structure, as described above, is appropriate in light of the size and complexity of the Fund, the number of Independent Directors (who constitute a super-majority of the Board s membership) and the Board s general oversight responsibility. The Board also believes that its leadership structure not only facilitates the orderly and efficient flow of information to the Independent Directors from management, including ClearBridge, the Fund s subadviser, but also enhances the independent and orderly exercise of its responsibilities.

#### **Audit Committee**

The Fund s Audit Committee is composed entirely of all of the Independent Directors: Mses. Colman and Kamerick and Messrs. Agdern, Cronin, Cucchi, Gelb, Hutchinson and Roett Ms. Kamerick serves as the Chair of the Audit Committee and has been determined by the Board to be an audit committee financial expert. The principal functions of the Audit Committee are: to (a) oversee the scope of the Fund s audit, the Fund s accounting and financial reporting policies and practices and its internal controls and enhance the quality and objectivity of the audit function; (b) approve, and recommend to the Independent Board Members (as such

term is defined in the Audit Committee Charter) for their ratification, the selection, appointment, retention or termination of the Fund s independent registered public accounting firm, as well as approving the compensation thereof; and (c) approve all audit and permissible non-audit services provided to the Fund and certain other persons by the Fund s independent registered public accounting firm. This Committee met two times during the fiscal year ended November 30, 2016. The Fund s Board of Directors most recently reviewed and adopted an Audit Committee Charter at a meeting held on February 11, 2014, a copy of which was attached as Annex A to the Fund s proxy statement dated February 20, 2015.

### **Nominating Committee**

The Fund s Nominating Committee, the principal function of which is to select and nominate candidates for election as Directors of the Fund, is composed of all of the Independent Directors: Mses. Colman and Kamerick and Messrs. Agdern, Cronin, Cucchi, Gelb, Hutchinson, and Roett. Mr. Cronin serves as the Chair of the Nominating Committee. The Nominating Committee may consider nominees recommended by the stockholder as it deems appropriate. Stockholders who wish to recommend a nominee should send recommendations to the Fund s Secretary that include all information relating to such person that is required to be disclosed in solicitations of proxies for the election of Directors. A recommendation must be accompanied by a written consent of the individual to stand for election if nominated by the Board of Directors and to serve if elected by the stockholders. The Nominating Committee met once during the fiscal year ended November 30, 2016. The Fund s Board of Directors most recently reviewed and adopted a Corporate Governance and Nominating Committee Charter at a meeting held on February 11, 2014, a copy of which was attached as Annex B to the Fund s proxy statement dated February 20, 2015.

The Nominating Committee identifies potential nominees through its network of contacts, and in its discretion may also engage a professional search firm. The Nominating Committee meets to discuss and consider such candidates qualifications and then chooses a candidate by majority vote. The Nominating Committee does not have specific, minimum qualifications for nominees and has not established specific qualities or skills that it regards as necessary for one or more of the Fund s Directors to possess (other than any qualities or skills that may be required by applicable law, regulation or listing standard). However, as set forth in the Nominating Committee Charter, in evaluating a person as a potential nominee to serve as a Director of the Fund, the Nominee Committee may consider the following factors, among any others it may deem relevant:

whether or not the person is an interested person as defined in the 1940 Act and whether the person is otherwise qualified under applicable laws and regulations to serve as a Director of the Fund;

whether or not the person has any relationships that might impair his or her independence, such as any business, financial or family relationships with Fund management, the investment manager of the Fund, Fund service providers or their affiliates;

whether or not the person serves on boards of, or is otherwise affiliated with, competing financial service organizations or their related mutual fund complexes;

whether or not the person is willing to serve, and willing and able to commit the time necessary for the performance of the duties of a Director of the Fund;

the contribution which the person can make to the Board and the Fund (or, if the person has previously served as a Director of the Fund, the contribution which the person made to the Board during his or her previous term of service), with consideration being given to the person s business and professional experience, education and such other factors as the Committee may consider relevant;

the character and integrity of the person; and

whether or not the selection and nomination of the person would be consistent with the requirements of the Fund s retirement policies.

The Nominating Committee does not have a formal diversity policy with regard to the consideration of diversity in identifying potential director nominees but may consider diversity of professional experience, education and skills when evaluating potential nominees for Board membership.

### **Pricing and Valuation Committee**

The Fund s Pricing and Valuation Committee is composed of all of the Independent Directors. The members of the Pricing and Valuation Committee are Mses. Colman and Kamerick and Messrs. Agdern, Cronin, Cucchi, Gelb, Hutchinson and Roett. Ms. Colman serves as Chair of the Fund s Pricing and Valuation Committee. The principal function of the Pricing and Valuation Committee is to assist the Board with its oversight of the process for valuing portfolio securities in light of applicable law, regulatory guidance and applicable policies and procedures adopted by the Fund. The Pricing and Valuation Committee met four times during the fiscal year ended November 30, 2016.

### **Compensation Committee**

The Fund s Compensation Committee is composed of all of the Independent Directors. The members of the Compensation Committee are Mses. Colman and Kamerick and Messrs. Agdern, Cronin, Cucchi, Gelb, Hutchinson and Roett. Mr. Cucchi serves as Chair of the Fund s Compensation Committee. The principal function of the Compensation Committee is to recommend the appropriate compensation of the Independent Directors for their service on the Board and the committees of the Board. The Fund s Compensation Committee was formed on January 1, 2016. The Compensation Committee met once during the fiscal year ended November 30, 2016. The Fund s Board of Directors have reviewed and adopted a Compensation Committee Charter, a copy of which is attached as Annex C.

### **Risk Oversight**

The Board s role in risk oversight of the Fund reflects its responsibility under applicable state law to oversee generally, rather than to manage, the operations of the Fund. In line with this oversight responsibility, the Board receives reports and makes inquiry at its regular meetings and as needed regarding the nature and extent of significant Fund risks (including investment, compliance and valuation risks) that potentially could have a materially adverse impact on the business operations, investment performance or reputation of the Fund, but relies upon the Fund s management (including the Fund s portfolio managers) and Chief Compliance Officer, who reports directly to the Board, and the Manager to assist it in identifying and understanding the nature and extent of such risks and determining whether, and to what extent, such risks may be eliminated or mitigated. In addition to reports and other information received from Fund management and the Manager regarding the Fund s investment program and activities, the Board as part of its risk oversight efforts meets at its regular meetings and as needed with the Fund s Chief Compliance Officer to discuss, among other things, risk issues and issues regarding the policies, procedures and controls of the Fund. The Board may be assisted in performing aspects of its role in risk oversight by the Audit Committee and such other standing or special committees as may be established from time to time by the Board. For example, the Audit Committee of the Board regularly meets with the Fund s independent public accounting firm to review, among other things, reports on the Fund s internal controls for financial reporting.

The Board believes that not all risks that may affect the Fund can be identified, that it may not be practical or cost-effective to eliminate or mitigate certain risks, that it may be necessary to bear certain risks (such as investment-related risks) to achieve the Fund s goals, and that the processes, procedures and controls employed to address certain risks may be limited in their effectiveness. Moreover, reports received by the Directors as to risk management matters are typically summaries of relevant information and may be inaccurate or incomplete. As a result of the foregoing and other factors, the Board s risk management oversight is subject to substantial limitations.

### **Officers**

The Fund s executive officers are chosen each year at a regular meeting of the Board of Directors of the Fund, to hold office until their respective successors are duly elected and qualified. Officers of the Fund receive no compensation from the Fund although they may be reimbursed by the Fund for reasonable out-of-pocket travel expenses for attending Board meetings. In addition to Ms. Trust, the Fund s Chairman, CEO and President, the executive officers of the Fund currently are:

Name, Address and Age	Position(s) Held with Fund	Length of Time Served	Principal Occupation(s) During Past 5 years
Richard F. Sennett Legg Mason & Co. 100 International Drive Baltimore, MD 21202 Birth year: 1970	Principal Financial Officer	Since 2012	Principal Financial Officer and Treasurer of certain mutual funds associated with Legg Mason & Co. or its affiliates (since 2011 and 2013); Managing Director of Legg Mason & Co. and Senior Manager of the Treasury Policy group for Legg Mason & Co. s Global Fiduciary Platform (since 2011); formerly, Chief Accountant within the SEC s Division of Investment Management (2007 to 2011); formerly, Assistant Chief Accountant within the SEC s Division of Investment Management (2002 to 2007)
Ted P. Becker Legg Mason & Co. 620 Eighth Avenue, 49th Floor New York, NY 10018 Birth year: 1951	Chief Compliance Officer	Since 2012	Director of Global Compliance at Legg Mason (since 2006); Managing Director of Compliance at Legg Mason, (since 2005); Chief Compliance Officer with certain mutual funds associated with Legg Mason (since 2006); Managing Director of Compliance at Legg Mason or its predecessors (2002-2005). Prior to 2002, Managing Director Internal Audit & Risk Review at Citigroup Inc.
Jenna Bailey Legg Mason & Co. 100 First Stamford Place,	Identity Theft Prevention Officer	Since 2015	Identity Theft Prevention Officer of certain mutual funds associated with Legg Mason & Co. or its affiliates

Edgar Filing: ClearBridge Energy MLP Total Return Fund Inc. - Form DEF 14A

Stamford, CT 06902	2
Birth year: 1978	

(since 2015); Compliance Officer of Legg Mason & Co. (since 2013); Associate Compliance Officer of Legg Mason & Co. (2011-2013); Assistant Vice President of Legg Mason & Co. (since 2011); formerly, Risk Manager of U.S. Distribution of Legg Mason & Co. (2007 to 2011).

Name, Address and Age	Position(s) Held with Fund	Length of Time Served	Principal Occupation(s) During Past 5 years
Steven Frank Legg Mason & Co. 620 Eighth Avenue, 49th Floor New York, NY 10018 Birth Year: 1967	Treasurer	Since 2012	Director of Legg Mason & Co. (since 2015); Treasurer of certain mutual funds associated with Legg Mason & Co. or its affiliates (since 2010); formerly Vice President of Legg Mason & Co. and Legg Mason & Co. predecessors (2002 to 2015); formerly, Controller of certain mutual funds associated with Legg Mason & Co. or its affiliates (prior to 2010)
Robert I. Frenkel Legg Mason & Co. 100 First Stamford Place Stamford, CT 06902 Birth year: 1954	Secretary and Chief Legal Officer	Since 2012	Managing Director and General Counsel of U.S. Mutual Funds for Legg Mason and its predecessor (since 1994); Secretary and Chief Legal Officer of mutual funds associated with Legg Mason (since 2003); formerly, Secretary of CFM (2001-2004)

### Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended (the 1934 Act ) and Section 30(h) of the 1940 Act in combination require the Fund s Directors and officers and persons who own more than 10% of the Fund s common stock, as well as LMPFA and certain of its affiliated persons, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (SEC) and the New York Stock Exchange, Inc. (NYSE). Such persons and entities are required by SEC regulations to furnish the Fund with copies of all such filings. Based solely on its review of the copies of such forms received by it, or written representations from certain reporting persons, the Fund believes that, during the fiscal year ended November 30, 2016, all such filing requirements were met with respect to the Fund, with the exception of initial statements of beneficial interest on Form 3 for John D. Kenney, Justin Eede, Brian Eakes and Terence Johnson, which were filed late due to an administrative oversight.

### **Report of the Audit Committee**

Pursuant to a meeting of the Audit Committee on January 19-20, 2017, the Audit Committee reports that it has: (i) reviewed and discussed the Fund s audited financial statements with management; (ii) discussed with KPMG LLP (KPMG), the independent registered public accounting firm of the Fund, the matters required to be discussed by Statement on Auditing Standards No. 61, as amended, as adopted by the Public Company Accounting Oversight Board in Rule 3200T; and (iii) previously received written confirmation from KPMG that it is independent and written disclosures regarding such independence as required by the Public Company Accounting Oversight Board Standard No. 1, and discussed with KPMG the independent registered public accounting firm s independence.